NanoVibronix, Inc. (NAOV) 10-Year Financial Performance & Capital Metrics

NAOV • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutNanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.Show more

Revenue $3M +12.0%
EBITDA -$4M -4.3%
Net Income -$4M +0.2%
EPS (Diluted) -13.73 +35.2%
Gross Margin 58.95% -12.4%
EBITDA Margin -139.99% +7.0%
Operating Margin -140.03% +7.0%
Net Margin -144.84% +10.9%
ROE -160.56% -56.2%
ROIC -766.48% -95.0%
Debt/Equity 0.19 +14653.4%
Interest Coverage -26.53 -90.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.0%
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 54.2% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y28.84%

5Y37%

3Y14.7%

TTM-18.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-15.71%

EPS CAGR

10Y-

5Y-

3Y-

TTM34.54%

ROCE

10Y Avg-165.47%

5Y Avg-111.12%

3Y Avg-108.51%

Latest-139.73%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	147K	229K	239K	318K	530K	623K	1.7M	752K	2.28M	2.56M
Revenue Growth %	-0.28%	0.56%	0.04%	0.33%	0.67%	0.18%	1.72%	-0.56%	2.04%	0.12%
Cost of Goods Sold+	49K	88K	88K	158K	249K	409K	925K	585K	746K	1.05M
COGS % of Revenue	0.33%	0.38%	0.37%	0.5%	0.47%	0.66%	0.55%	0.78%	0.33%	0.41%
Gross Profit+	98K	141K	151K	160K	281K	214K	770K	167K	1.54M	1.51M
Gross Margin %	0.67%	0.62%	0.63%	0.5%	0.53%	0.34%	0.45%	0.22%	0.67%	0.59%
Gross Profit Growth %	-0.11%	0.44%	0.07%	0.06%	0.76%	-0.24%	2.6%	-0.78%	8.2%	-0.02%
Operating Expenses+	1.52M	2.46M	3.24M	4.46M	5.43M	4.93M	6.45M	5.18M	4.97M	5.09M
OpEx % of Revenue	10.36%	10.73%	13.56%	14.03%	10.25%	7.92%	3.81%	6.89%	2.18%	1.99%
Selling, General & Admin	1.12M	1.87M	2.55M	3.85M	4.92M	4.76M	6.16M	4.9M	4.79M	4.18M
SG&A % of Revenue	7.65%	8.18%	10.67%	12.1%	9.28%	7.64%	3.63%	6.51%	2.1%	1.63%
Research & Development	399K	584K	693K	614K	514K	171K	293K	283K	185K	909K
R&D % of Revenue	2.71%	2.55%	2.9%	1.93%	0.97%	0.27%	0.17%	0.38%	0.08%	0.36%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-1.42M	-2.32M	-3.09M	-4.3M	-5.15M	-4.72M	-5.68M	-5.01M	-3.44M	-3.58M
Operating Margin %	-9.69%	-10.11%	-12.93%	-13.53%	-9.72%	-7.57%	-3.35%	-6.66%	-1.51%	-1.4%
Operating Income Growth %	-0.18%	-0.63%	-0.33%	-0.39%	-0.2%	0.08%	-0.2%	0.12%	0.31%	-0.04%
EBITDA+	-1.42M	-2.31M	-3.09M	-4.3M	-5.15M	-4.72M	-5.68M	-5.01M	-3.44M	-3.58M
EBITDA Margin %	-9.63%	-10.08%	-12.91%	-13.51%	-9.71%	-7.57%	-3.35%	-6.66%	-1.5%	-1.4%
EBITDA Growth %	-0.18%	-0.63%	-0.34%	-0.39%	-0.2%	0.08%	-0.2%	0.12%	0.31%	-0.04%
D&A (Non-Cash Add-back)	9K	7K	5K	6K	4K	2K	2K	1K	1K	1K
EBIT	-2.39M	-2.7M	-3.64M	-4.28M	-5.75M	-4.16M	-14.25M	-5.41M	-3.55M	-3.69M
Net Interest Income+	-470K	-15K	-1.29M	22K	-62K	-147K	0	-347K	-246K	-104K
Interest Income	0	0	0	0	0	0	0	0	0	31K
Interest Expense	65K	15K	1.23M	22K	62K	147K	0	347K	246K	135K
Other Income/Expense	-1.43M	-398K	-1.84M	22K	-660K	408K	-8.57M	-401K	-246K	-104K
Pretax Income+	-2.86M	-2.71M	-4.93M	-4.28M	-5.81M	-4.31M	-14.25M	-5.41M	-3.68M	-3.69M
Pretax Margin %	-19.43%	-11.85%	-20.62%	-13.46%	-10.96%	-6.92%	-8.41%	-7.2%	-1.61%	-1.44%
Income Tax+	28K	117K	38K	-127K	-17K	15K	32K	35K	29K	19K
Effective Tax Rate %	1.01%	1.04%	1.01%	0.97%	1%	1%	1%	1.01%	1.01%	1.01%
Net Income+	-2.88M	-2.83M	-4.96M	-4.15M	-5.79M	-4.33M	-14.28M	-5.45M	-3.71M	-3.71M
Net Margin %	-19.62%	-12.36%	-20.77%	-13.06%	-10.93%	-6.94%	-8.43%	-7.24%	-1.63%	-1.45%
Net Income Growth %	-0.09%	0.02%	-0.75%	0.16%	-0.39%	0.25%	-2.3%	0.62%	0.32%	0%
Net Income (Continuing)	-2.88M	-2.83M	-4.96M	-4.15M	-5.79M	-4.33M	-14.28M	-5.45M	-3.71M	-3.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-163.10	-123.70	-200.00	-128.80	-167.00	-84.00	-113.50	-38.40	-21.20	-13.73
EPS Growth %	0.2%	0.24%	-0.62%	0.36%	-0.3%	0.5%	-0.35%	0.66%	0.45%	0.35%
EPS (Basic)	-163.10	-123.70	-200.00	-128.80	-167.00	-84.00	-113.50	-38.40	-21.20	-13.73
Diluted Shares Outstanding	17.68K	22.89K	24.82K	32.24K	34.7K	51.49K	125.81K	141.97K	175.01K	269.85K
Basic Shares Outstanding	17.68K	22.89K	24.82K	32.24K	34.7K	51.49K	125.81K	141.97K	175.01K	269.85K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.78M	221K	4.52M	1.23M	1.84M	7.97M	8.34M	5.61M	6.49M	3.33M
Cash & Short-Term Investments	1.61M	106K	4.36M	896K	1.34M	7.14M	7.74M	2.71M	3.28M	752K
Cash Only	1.61M	106K	4.36M	896K	1.34M	7.14M	7.74M	2.71M	3.28M	752K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	41K	14K	35K	144K	130K	93K	200K	109K	425K	268K
Days Sales Outstanding	101.8	22.31	53.45	165.28	89.53	54.49	43.07	52.91	67.95	38.24
Inventory	71K	67K	76K	144K	121K	145K	175K	2.17M	2.73M	2.19M
Days Inventory Outstanding	528.88	277.9	315.23	332.66	177.37	129.4	69.05	1.36K	1.34K	761.63
Other Current Assets	0	0	5K	0	0	391K	64K	0	0	98K
Total Non-Current Assets+	207K	273K	349K	354K	198K	259K	280K	270K	187K	298K
Property, Plant & Equipment	10K	11K	6K	8K	4K	35K	54K	88K	12K	125K
Fixed Asset Turnover	14.70x	20.82x	39.83x	39.75x	132.50x	17.80x	31.39x	8.55x	190.25x	20.46x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	19K	3K	1K	0
Other Non-Current Assets	197K	262K	343K	346K	194K	224K	207K	179K	174K	173K
Total Assets+	1.98M	494K	4.87M	1.58M	2.04M	8.23M	8.62M	5.88M	6.67M	3.63M
Asset Turnover	0.07x	0.46x	0.05x	0.20x	0.26x	0.08x	0.20x	0.13x	0.34x	0.70x
Asset Growth %	1.74%	-0.75%	8.85%	-0.68%	0.29%	3.04%	0.05%	-0.32%	0.14%	-0.46%
Total Current Liabilities+	297K	565K	797K	640K	409K	2.9M	1.9M	2.32M	2.45M	2.72M
Accounts Payable	58K	82K	168K	193K	129K	144K	87K	66K	138K	47K
Days Payables Outstanding	432.04	340.11	696.82	445.85	189.1	128.51	34.33	41.18	67.52	16.34
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	21K	46K	15K
Other Current Liabilities	144K	313K	410K	447K	280K	2.26M	1.77M	2.15M	2.27M	47K
Current Ratio	5.98x	0.39x	5.67x	1.92x	4.49x	2.75x	4.38x	2.42x	2.64x	1.22x
Quick Ratio	5.74x	0.27x	5.57x	1.69x	4.20x	2.70x	4.29x	1.48x	1.53x	0.42x
Cash Conversion Cycle	198.64	-39.9	-328.14	52.09	77.8	55.38	77.79	1.37K	1.34K	783.54
Total Non-Current Liabilities+	1.9M	2.43M	434K	477K	279K	2.93M	406K	330K	232K	280K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	18K	0	0	0	64K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.9M	2.43M	434K	477K	279K	2.72M	406K	223K	217K	216K
Total Liabilities	2.19M	2.99M	1.23M	1.12M	688K	5.83M	2.31M	2.65M	2.69M	3M
Total Debt+	0	0	0	0	0	31K	49K	81K	5K	116K
Net Debt	-1.61M	-106K	-4.36M	-896K	-1.34M	-7.11M	-7.69M	-2.63M	-3.28M	-636K
Debt / Equity	-	-	-	-	-	0.01x	0.01x	0.03x	0.00x	0.19x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-21.91x	-154.40x	-2.50x	-195.59x	-83.08x	-32.10x	-	-14.44x	-13.97x	-26.53x
Total Equity+	-209K	-2.5M	3.63M	463K	1.35M	2.39M	6.31M	3.23M	3.99M	627K
Equity Growth %	0.96%	-10.96%	2.45%	-0.87%	1.91%	0.78%	1.64%	-0.49%	0.23%	-0.84%
Book Value per Share	-11.82	-109.16	146.41	14.36	38.85	46.49	50.18	22.77	22.79	2.32
Total Shareholders' Equity	-209K	-2.5M	3.63M	463K	1.35M	2.39M	6.31M	3.23M	3.99M	627K
Common Stock	2K	2K	4K	4K	5K	22K	1K	2K	2K	3K
Retained Earnings	-19.73M	-22.58M	-28.38M	-32.54M	-38.33M	-42.66M	-56.94M	-62.38M	-66.1M	-69.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-100K	-40K	-45K	-50K	0	66K	60K	-18K	-67K	-80K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.48M	-1.53M	-2.18M	-3.55M	-3.87M	-3.39M	-4.37M	-7.04M	-3.6M	-2.52M
Operating CF Margin %	-10.07%	-6.69%	-9.13%	-11.16%	-7.31%	-5.44%	-2.58%	-9.36%	-1.58%	-0.98%
Operating CF Growth %	-0.64%	-0.04%	-0.42%	-0.63%	-0.09%	0.12%	-0.29%	-0.61%	0.49%	0.3%
Net Income	-2.88M	-2.83M	-4.96M	-4.15M	-5.79M	-4.33M	-14.28M	-5.45M	-3.71M	-3.71M
Depreciation & Amortization	9K	7K	5K	6K	4K	2K	2K	1K	1K	1K
Stock-Based Compensation	220K	508K	800K	889K	1.75M	376K	382K	354K	293K	356K
Deferred Taxes	962K	0	549K	0	598K	-536K	8.53M	0	0	0
Other Non-Cash Items	449K	383K	1.2M	1.01M	10K	647K	1.5M	363K	137K	101K
Working Capital Changes	-236K	400K	232K	-291K	-447K	445K	-494K	-2.31M	-322K	731K
Change in Receivables	16K	-1K	-18K	-71K	-16K	86K	-175K	191K	-309K	85K
Change in Inventory	-36K	4K	-9K	-68K	23K	-26K	-30K	-2M	-557K	541K
Change in Payables	-43K	24K	86K	25K	-64K	15K	-59K	-21K	54K	-91K
Cash from Investing+	-1K	-8K	0	-8K	0	-2K	-3K	-3K	-1K	-3K
Capital Expenditures	-1K	-8K	0	-8K	0	-2K	-3K	-3K	-1K	-3K
CapEx % of Revenue	0.01%	0.03%	-	0.03%	-	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	3M	33K	6.44M	94K	4.32M	9.52M	4.58M	2.09M	4.22M	1K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	33K	0	94K	66K	1K	-388K	2K	7K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.48M	-1.54M	-2.18M	-3.56M	-3.87M	-3.39M	-4.37M	-7.04M	-3.6M	-2.52M
FCF Margin %	-10.07%	-6.73%	-9.13%	-11.19%	-7.31%	-5.45%	-2.58%	-9.36%	-1.58%	-0.98%
FCF Growth %	-0.64%	-0.04%	-0.42%	-0.63%	-0.09%	0.12%	-0.29%	-0.61%	0.49%	0.3%
FCF per Share	-83.76	-67.32	-87.91	-110.35	-111.66	-65.90	-34.73	-49.57	-20.59	-9.33
FCF Conversion (FCF/Net Income)	0.51x	0.54x	0.44x	0.85x	0.67x	0.78x	0.31x	1.29x	0.97x	0.68x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-874.89%	-202.78%	-639.87%	-231.21%	-328.06%	-114.14%	-102.78%	-160.56%
Return on Invested Capital (ROIC)	-	-	-	-	-38632.5%	-	-	-625.46%	-393.13%	-766.48%
Gross Margin	66.67%	61.57%	63.18%	50.31%	53.02%	34.35%	45.43%	22.21%	67.32%	58.95%
Net Margin	-1961.9%	-1236.24%	-2077.41%	-1306.29%	-1093.21%	-694.38%	-842.6%	-724.47%	-162.55%	-144.84%
Debt / Equity	-	-	-	-	-	0.01x	0.01x	0.03x	0.00x	0.19x
Interest Coverage	-21.91x	-154.40x	-2.50x	-195.59x	-83.08x	-32.10x	-	-14.44x	-13.97x	-26.53x
FCF Conversion	0.51x	0.54x	0.44x	0.85x	0.67x	0.78x	0.31x	1.29x	0.97x	0.68x
Revenue Growth	-27.59%	55.78%	4.37%	33.05%	66.67%	17.55%	172.07%	-55.63%	203.59%	12.05%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other Country	-	-	-	-	-	-	-	5K	-	46K
Other Country Growth	-	-	-	-	-	-	-	-	-	-
AUSTRALIA	-	-	-	-	-	-	-	9K	19M	29K
AUSTRALIA Growth	-	-	-	-	-	-	-	-	211011.11%	-99.85%
Europe	28K	52K	-	-	168K	147K	18K	25K	101M	17K
Europe Growth	-	85.71%	-	-	-	-12.50%	-87.76%	38.89%	403900.00%	-99.98%
NEW ZEALAND	-	-	-	-	-	-	-	-	-	12K
NEW ZEALAND Growth	-	-	-	-	-	-	-	-	-	-
ISRAEL	14K	13K	8K	-	-	-	5K	-	1M	4K
ISRAEL Growth	-	-7.14%	-38.46%	-	-	-	-	-	-	-99.60%
UNITED STATES	52K	89K	90K	-	-	-	1.63M	710K	2.16B	-
UNITED STATES Growth	-	71.15%	1.12%	-	-	-	-	-56.36%	304407.04%	-
INDIA	7K	24K	14K	-	-	-	-	3K	-	-
INDIA Growth	-	242.86%	-41.67%	-	-	-	-	-	-	-
Other country	-	-	-	-	-	-	45K	-	-	-
Other country Growth	-	-	-	-	-	-	-	-	-	-
United States	-	-	-	164K	331K	467K	-	-	-	-
United States Growth	-	-	-	-	101.83%	41.09%	-	-	-	-
Other	-	-	39K	30K	5K	5K	-	-	-	-
Other Growth	-	-	-	-23.08%	-83.33%	0.00%	-	-	-	-
Israel	-	-	-	49K	14K	3K	-	-	-	-
Israel Growth	-	-	-	-	-71.43%	-78.57%	-	-	-	-
India	-	-	-	17K	12K	1K	-	-	-	-
India Growth	-	-	-	-	-29.41%	-91.67%	-	-	-	-
European Union (excluding United Kingdom)	-	-	14K	8K	-	-	-	-	-	-
European Union (excluding United Kingdom) Growth	-	-	-	-42.86%	-	-	-	-	-	-
World	46K	51K	-	-	-	-	-	-	-	-
World Growth	-	10.87%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NanoVibronix, Inc. (NAOV) reported $2.7M in revenue for fiscal year 2024. This represents a 2756% increase from $0.1M in 2011.

NanoVibronix, Inc. (NAOV) grew revenue by 12.0% over the past year. This is steady growth.

NanoVibronix, Inc. (NAOV) reported a net loss of $3.6M for fiscal year 2024.

Dividend & Returns

NanoVibronix, Inc. (NAOV) has a return on equity (ROE) of -160.6%. Negative ROE indicates the company is unprofitable.

NanoVibronix, Inc. (NAOV) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

NanoVibronix, Inc. (NAOV) 10-Year Financial Performance & Capital Metrics

NAOV • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

Revenue $3M +12.0%
EBITDA -$4M -4.3%
Net Income -$4M +0.2%
EPS (Diluted) -13.73 +35.2%
Gross Margin 58.95% -12.4%
EBITDA Margin -139.99% +7.0%
Operating Margin -140.03% +7.0%
Net Margin -144.84% +10.9%
ROE -160.56% -56.2%
ROIC -766.48% -95.0%
Debt/Equity 0.19 +14653.4%
Interest Coverage -26.53 -90.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.0%
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 54.2% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y28.84%

5Y37%

3Y14.7%

TTM-18.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-15.71%

EPS CAGR

10Y-

5Y-

3Y-

TTM34.54%

ROCE

10Y Avg-165.47%

5Y Avg-111.12%

3Y Avg-108.51%

Latest-139.73%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	147K	229K	239K	318K	530K	623K	1.7M	752K	2.28M	2.56M
Revenue Growth %	-0.28%	0.56%	0.04%	0.33%	0.67%	0.18%	1.72%	-0.56%	2.04%	0.12%
Cost of Goods Sold+	49K	88K	88K	158K	249K	409K	925K	585K	746K	1.05M
COGS % of Revenue	0.33%	0.38%	0.37%	0.5%	0.47%	0.66%	0.55%	0.78%	0.33%	0.41%
Gross Profit+	98K	141K	151K	160K	281K	214K	770K	167K	1.54M	1.51M
Gross Margin %	0.67%	0.62%	0.63%	0.5%	0.53%	0.34%	0.45%	0.22%	0.67%	0.59%
Gross Profit Growth %	-0.11%	0.44%	0.07%	0.06%	0.76%	-0.24%	2.6%	-0.78%	8.2%	-0.02%
Operating Expenses+	1.52M	2.46M	3.24M	4.46M	5.43M	4.93M	6.45M	5.18M	4.97M	5.09M
OpEx % of Revenue	10.36%	10.73%	13.56%	14.03%	10.25%	7.92%	3.81%	6.89%	2.18%	1.99%
Selling, General & Admin	1.12M	1.87M	2.55M	3.85M	4.92M	4.76M	6.16M	4.9M	4.79M	4.18M
SG&A % of Revenue	7.65%	8.18%	10.67%	12.1%	9.28%	7.64%	3.63%	6.51%	2.1%	1.63%
Research & Development	399K	584K	693K	614K	514K	171K	293K	283K	185K	909K
R&D % of Revenue	2.71%	2.55%	2.9%	1.93%	0.97%	0.27%	0.17%	0.38%	0.08%	0.36%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-1.42M	-2.32M	-3.09M	-4.3M	-5.15M	-4.72M	-5.68M	-5.01M	-3.44M	-3.58M
Operating Margin %	-9.69%	-10.11%	-12.93%	-13.53%	-9.72%	-7.57%	-3.35%	-6.66%	-1.51%	-1.4%
Operating Income Growth %	-0.18%	-0.63%	-0.33%	-0.39%	-0.2%	0.08%	-0.2%	0.12%	0.31%	-0.04%
EBITDA+	-1.42M	-2.31M	-3.09M	-4.3M	-5.15M	-4.72M	-5.68M	-5.01M	-3.44M	-3.58M
EBITDA Margin %	-9.63%	-10.08%	-12.91%	-13.51%	-9.71%	-7.57%	-3.35%	-6.66%	-1.5%	-1.4%
EBITDA Growth %	-0.18%	-0.63%	-0.34%	-0.39%	-0.2%	0.08%	-0.2%	0.12%	0.31%	-0.04%
D&A (Non-Cash Add-back)	9K	7K	5K	6K	4K	2K	2K	1K	1K	1K
EBIT	-2.39M	-2.7M	-3.64M	-4.28M	-5.75M	-4.16M	-14.25M	-5.41M	-3.55M	-3.69M
Net Interest Income+	-470K	-15K	-1.29M	22K	-62K	-147K	0	-347K	-246K	-104K
Interest Income	0	0	0	0	0	0	0	0	0	31K
Interest Expense	65K	15K	1.23M	22K	62K	147K	0	347K	246K	135K
Other Income/Expense	-1.43M	-398K	-1.84M	22K	-660K	408K	-8.57M	-401K	-246K	-104K
Pretax Income+	-2.86M	-2.71M	-4.93M	-4.28M	-5.81M	-4.31M	-14.25M	-5.41M	-3.68M	-3.69M
Pretax Margin %	-19.43%	-11.85%	-20.62%	-13.46%	-10.96%	-6.92%	-8.41%	-7.2%	-1.61%	-1.44%
Income Tax+	28K	117K	38K	-127K	-17K	15K	32K	35K	29K	19K
Effective Tax Rate %	1.01%	1.04%	1.01%	0.97%	1%	1%	1%	1.01%	1.01%	1.01%
Net Income+	-2.88M	-2.83M	-4.96M	-4.15M	-5.79M	-4.33M	-14.28M	-5.45M	-3.71M	-3.71M
Net Margin %	-19.62%	-12.36%	-20.77%	-13.06%	-10.93%	-6.94%	-8.43%	-7.24%	-1.63%	-1.45%
Net Income Growth %	-0.09%	0.02%	-0.75%	0.16%	-0.39%	0.25%	-2.3%	0.62%	0.32%	0%
Net Income (Continuing)	-2.88M	-2.83M	-4.96M	-4.15M	-5.79M	-4.33M	-14.28M	-5.45M	-3.71M	-3.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-163.10	-123.70	-200.00	-128.80	-167.00	-84.00	-113.50	-38.40	-21.20	-13.73
EPS Growth %	0.2%	0.24%	-0.62%	0.36%	-0.3%	0.5%	-0.35%	0.66%	0.45%	0.35%
EPS (Basic)	-163.10	-123.70	-200.00	-128.80	-167.00	-84.00	-113.50	-38.40	-21.20	-13.73
Diluted Shares Outstanding	17.68K	22.89K	24.82K	32.24K	34.7K	51.49K	125.81K	141.97K	175.01K	269.85K
Basic Shares Outstanding	17.68K	22.89K	24.82K	32.24K	34.7K	51.49K	125.81K	141.97K	175.01K	269.85K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.78M	221K	4.52M	1.23M	1.84M	7.97M	8.34M	5.61M	6.49M	3.33M
Cash & Short-Term Investments	1.61M	106K	4.36M	896K	1.34M	7.14M	7.74M	2.71M	3.28M	752K
Cash Only	1.61M	106K	4.36M	896K	1.34M	7.14M	7.74M	2.71M	3.28M	752K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	41K	14K	35K	144K	130K	93K	200K	109K	425K	268K
Days Sales Outstanding	101.8	22.31	53.45	165.28	89.53	54.49	43.07	52.91	67.95	38.24
Inventory	71K	67K	76K	144K	121K	145K	175K	2.17M	2.73M	2.19M
Days Inventory Outstanding	528.88	277.9	315.23	332.66	177.37	129.4	69.05	1.36K	1.34K	761.63
Other Current Assets	0	0	5K	0	0	391K	64K	0	0	98K
Total Non-Current Assets+	207K	273K	349K	354K	198K	259K	280K	270K	187K	298K
Property, Plant & Equipment	10K	11K	6K	8K	4K	35K	54K	88K	12K	125K
Fixed Asset Turnover	14.70x	20.82x	39.83x	39.75x	132.50x	17.80x	31.39x	8.55x	190.25x	20.46x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	19K	3K	1K	0
Other Non-Current Assets	197K	262K	343K	346K	194K	224K	207K	179K	174K	173K
Total Assets+	1.98M	494K	4.87M	1.58M	2.04M	8.23M	8.62M	5.88M	6.67M	3.63M
Asset Turnover	0.07x	0.46x	0.05x	0.20x	0.26x	0.08x	0.20x	0.13x	0.34x	0.70x
Asset Growth %	1.74%	-0.75%	8.85%	-0.68%	0.29%	3.04%	0.05%	-0.32%	0.14%	-0.46%
Total Current Liabilities+	297K	565K	797K	640K	409K	2.9M	1.9M	2.32M	2.45M	2.72M
Accounts Payable	58K	82K	168K	193K	129K	144K	87K	66K	138K	47K
Days Payables Outstanding	432.04	340.11	696.82	445.85	189.1	128.51	34.33	41.18	67.52	16.34
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	21K	46K	15K
Other Current Liabilities	144K	313K	410K	447K	280K	2.26M	1.77M	2.15M	2.27M	47K
Current Ratio	5.98x	0.39x	5.67x	1.92x	4.49x	2.75x	4.38x	2.42x	2.64x	1.22x
Quick Ratio	5.74x	0.27x	5.57x	1.69x	4.20x	2.70x	4.29x	1.48x	1.53x	0.42x
Cash Conversion Cycle	198.64	-39.9	-328.14	52.09	77.8	55.38	77.79	1.37K	1.34K	783.54
Total Non-Current Liabilities+	1.9M	2.43M	434K	477K	279K	2.93M	406K	330K	232K	280K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	18K	0	0	0	64K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.9M	2.43M	434K	477K	279K	2.72M	406K	223K	217K	216K
Total Liabilities	2.19M	2.99M	1.23M	1.12M	688K	5.83M	2.31M	2.65M	2.69M	3M
Total Debt+	0	0	0	0	0	31K	49K	81K	5K	116K
Net Debt	-1.61M	-106K	-4.36M	-896K	-1.34M	-7.11M	-7.69M	-2.63M	-3.28M	-636K
Debt / Equity	-	-	-	-	-	0.01x	0.01x	0.03x	0.00x	0.19x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-21.91x	-154.40x	-2.50x	-195.59x	-83.08x	-32.10x	-	-14.44x	-13.97x	-26.53x
Total Equity+	-209K	-2.5M	3.63M	463K	1.35M	2.39M	6.31M	3.23M	3.99M	627K
Equity Growth %	0.96%	-10.96%	2.45%	-0.87%	1.91%	0.78%	1.64%	-0.49%	0.23%	-0.84%
Book Value per Share	-11.82	-109.16	146.41	14.36	38.85	46.49	50.18	22.77	22.79	2.32
Total Shareholders' Equity	-209K	-2.5M	3.63M	463K	1.35M	2.39M	6.31M	3.23M	3.99M	627K
Common Stock	2K	2K	4K	4K	5K	22K	1K	2K	2K	3K
Retained Earnings	-19.73M	-22.58M	-28.38M	-32.54M	-38.33M	-42.66M	-56.94M	-62.38M	-66.1M	-69.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-100K	-40K	-45K	-50K	0	66K	60K	-18K	-67K	-80K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.48M	-1.53M	-2.18M	-3.55M	-3.87M	-3.39M	-4.37M	-7.04M	-3.6M	-2.52M
Operating CF Margin %	-10.07%	-6.69%	-9.13%	-11.16%	-7.31%	-5.44%	-2.58%	-9.36%	-1.58%	-0.98%
Operating CF Growth %	-0.64%	-0.04%	-0.42%	-0.63%	-0.09%	0.12%	-0.29%	-0.61%	0.49%	0.3%
Net Income	-2.88M	-2.83M	-4.96M	-4.15M	-5.79M	-4.33M	-14.28M	-5.45M	-3.71M	-3.71M
Depreciation & Amortization	9K	7K	5K	6K	4K	2K	2K	1K	1K	1K
Stock-Based Compensation	220K	508K	800K	889K	1.75M	376K	382K	354K	293K	356K
Deferred Taxes	962K	0	549K	0	598K	-536K	8.53M	0	0	0
Other Non-Cash Items	449K	383K	1.2M	1.01M	10K	647K	1.5M	363K	137K	101K
Working Capital Changes	-236K	400K	232K	-291K	-447K	445K	-494K	-2.31M	-322K	731K
Change in Receivables	16K	-1K	-18K	-71K	-16K	86K	-175K	191K	-309K	85K
Change in Inventory	-36K	4K	-9K	-68K	23K	-26K	-30K	-2M	-557K	541K
Change in Payables	-43K	24K	86K	25K	-64K	15K	-59K	-21K	54K	-91K
Cash from Investing+	-1K	-8K	0	-8K	0	-2K	-3K	-3K	-1K	-3K
Capital Expenditures	-1K	-8K	0	-8K	0	-2K	-3K	-3K	-1K	-3K
CapEx % of Revenue	0.01%	0.03%	-	0.03%	-	0%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	3M	33K	6.44M	94K	4.32M	9.52M	4.58M	2.09M	4.22M	1K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	33K	0	94K	66K	1K	-388K	2K	7K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.48M	-1.54M	-2.18M	-3.56M	-3.87M	-3.39M	-4.37M	-7.04M	-3.6M	-2.52M
FCF Margin %	-10.07%	-6.73%	-9.13%	-11.19%	-7.31%	-5.45%	-2.58%	-9.36%	-1.58%	-0.98%
FCF Growth %	-0.64%	-0.04%	-0.42%	-0.63%	-0.09%	0.12%	-0.29%	-0.61%	0.49%	0.3%
FCF per Share	-83.76	-67.32	-87.91	-110.35	-111.66	-65.90	-34.73	-49.57	-20.59	-9.33
FCF Conversion (FCF/Net Income)	0.51x	0.54x	0.44x	0.85x	0.67x	0.78x	0.31x	1.29x	0.97x	0.68x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-874.89%	-202.78%	-639.87%	-231.21%	-328.06%	-114.14%	-102.78%	-160.56%
Return on Invested Capital (ROIC)	-	-	-	-	-38632.5%	-	-	-625.46%	-393.13%	-766.48%
Gross Margin	66.67%	61.57%	63.18%	50.31%	53.02%	34.35%	45.43%	22.21%	67.32%	58.95%
Net Margin	-1961.9%	-1236.24%	-2077.41%	-1306.29%	-1093.21%	-694.38%	-842.6%	-724.47%	-162.55%	-144.84%
Debt / Equity	-	-	-	-	-	0.01x	0.01x	0.03x	0.00x	0.19x
Interest Coverage	-21.91x	-154.40x	-2.50x	-195.59x	-83.08x	-32.10x	-	-14.44x	-13.97x	-26.53x
FCF Conversion	0.51x	0.54x	0.44x	0.85x	0.67x	0.78x	0.31x	1.29x	0.97x	0.68x
Revenue Growth	-27.59%	55.78%	4.37%	33.05%	66.67%	17.55%	172.07%	-55.63%	203.59%	12.05%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other Country	-	-	-	-	-	-	-	5K	-	46K
Other Country Growth	-	-	-	-	-	-	-	-	-	-
AUSTRALIA	-	-	-	-	-	-	-	9K	19M	29K
AUSTRALIA Growth	-	-	-	-	-	-	-	-	211011.11%	-99.85%
Europe	28K	52K	-	-	168K	147K	18K	25K	101M	17K
Europe Growth	-	85.71%	-	-	-	-12.50%	-87.76%	38.89%	403900.00%	-99.98%
NEW ZEALAND	-	-	-	-	-	-	-	-	-	12K
NEW ZEALAND Growth	-	-	-	-	-	-	-	-	-	-
ISRAEL	14K	13K	8K	-	-	-	5K	-	1M	4K
ISRAEL Growth	-	-7.14%	-38.46%	-	-	-	-	-	-	-99.60%
UNITED STATES	52K	89K	90K	-	-	-	1.63M	710K	2.16B	-
UNITED STATES Growth	-	71.15%	1.12%	-	-	-	-	-56.36%	304407.04%	-
INDIA	7K	24K	14K	-	-	-	-	3K	-	-
INDIA Growth	-	242.86%	-41.67%	-	-	-	-	-	-	-
Other country	-	-	-	-	-	-	45K	-	-	-
Other country Growth	-	-	-	-	-	-	-	-	-	-
United States	-	-	-	164K	331K	467K	-	-	-	-
United States Growth	-	-	-	-	101.83%	41.09%	-	-	-	-
Other	-	-	39K	30K	5K	5K	-	-	-	-
Other Growth	-	-	-	-23.08%	-83.33%	0.00%	-	-	-	-
Israel	-	-	-	49K	14K	3K	-	-	-	-
Israel Growth	-	-	-	-	-71.43%	-78.57%	-	-	-	-
India	-	-	-	17K	12K	1K	-	-	-	-
India Growth	-	-	-	-	-29.41%	-91.67%	-	-	-	-
European Union (excluding United Kingdom)	-	-	14K	8K	-	-	-	-	-	-
European Union (excluding United Kingdom) Growth	-	-	-	-42.86%	-	-	-	-	-	-
World	46K	51K	-	-	-	-	-	-	-	-
World Growth	-	10.87%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

NanoVibronix, Inc. (NAOV) reported $2.7M in revenue for fiscal year 2024. This represents a 2756% increase from $0.1M in 2011.

NanoVibronix, Inc. (NAOV) grew revenue by 12.0% over the past year. This is steady growth.

NanoVibronix, Inc. (NAOV) reported a net loss of $3.6M for fiscal year 2024.

Dividend & Returns

NanoVibronix, Inc. (NAOV) has a return on equity (ROE) of -160.6%. Negative ROE indicates the company is unprofitable.

NanoVibronix, Inc. (NAOV) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.